Quelltext anzeigen

Du bist nicht berechtigt, die Seite zu bearbeiten. Grund:

Du kannst den Quelltext dieser Seite betrachten und kopieren:

{{up|PHA Biologicals}} {{tp|p=32149773|t=ä. Effectiveness of glucocorticoid therapy in patients with severe coronavirus disease 2019: protocol of a randomized controlled trial |pdf=|usr=}} {{tp|p=32272008|t=2020. Early preemptive immunomodulators (corticosteroids) for severe pneumonia patients infected with SARS-CoV-2 |pdf=|usr=}} {{tp|p=32341100|t=2020. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective |pdf=|usr=}} {{tp|p=32321620|t=ä. Corticosteroid use for 2019-nCoV infection: A double-edged sword |pdf=|usr=}} {{tp|p=32283153|t=ä. Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-1 |pdf=|usr=}} {{tp|p=32389783|t=2020. Re: Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19.|pdf=|usr=008}} {{tp|p=32122468|t=2020. On the use of corticosteroids for 2019-nCoV pneumonia |pdf=|usr=}} {{tp|p=32043983|t=2020. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury |pdf=|usr=}} {{tp|p=32372026|t=ä. Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis |pdf=|usr=}} {{tp|p=32341331|t=2020. A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia |pdf=|usr=}} {{tp|p=32133159|t=2020. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia |pdf=|usr=}} {{tp|p=32266987|t=2020. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19) |pdf=|usr=}} {{tp|p=32164084|t=2020. Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia |pdf=|usr=}} {{tp|p=32296012|t=2020. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia |pdf=|usr=}} {{tp|p=C7189003|t=2020. Glukokortikoide und Covid-19 |pdf=|usr=}} {{tp|p=32475851|t=2020. COVID-19: Stay Cool toward Corticosteroids.|pdf=|usr=007}} {{tp|p=32409522|t=2020. Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis.|pdf=|usr=007}} {{tp|p=32427279|t=2020. Early Short Course Corticosteroids in Hospitalized Patients with COVID-19.|pdf=|usr=007}} {{tp|p=32474331|t=2020. Corticosteroids and the hyper-inflammatory phase of the COVID-19 disease.|pdf=|usr=008}} {{tp|p=32514902|t=2020. Systemic steroids in patients with COVID-19: pros and contras, an endocrinological point of view.|pdf=|usr=008}} {{tp|p=32283144|t=2020. The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis.|pdf=|usr=008}} {{tp|p=32391369|t=2020. Use of Corticosteroids in Coronavirus Disease 2019 Pneumonia: A Systematic Review of the Literature.|pdf=|usr=008}} {{tp|p=32417314|t=2020. Corticosteroid use in selected patients with severe acute respiratory distress syndrome related to COVID-19.|pdf=|usr=008}} {{tp|p=32437628|t=2020. COVID-19, Asthma, and Inhaled Corticosteroids (ICS): Another Beneficial Effect of ICS?|pdf=|usr=007}} {{tp|p=32470160|t=2020. Glucocorticoid therapy delays the clearance of SARS-CoV-2 RNA in an asymptomatic COVID-19 patient.|pdf=|usr=007}} {{tp|p=32441786|t=2020. Effects of methylprednisolone use on viral genomic nucleic acid negative conversion and CT imaging lesion absorption in COVID-19 patients under 50 years old.|pdf=|usr=007}} {{tp|p=32034899|t=2020. [Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia].|pdf=|usr=007}} {{tp|p=32479759|t=2020. Successful use of methylprednisolone for treating severe COVID-19.|pdf=|usr=008}} {{tp|p=32496422|t=2020. Effects of Corticosteroid Treatment for Non-Severe COVID-19 Pneumonia: A Propensity Score-Based Analysis.|pdf=|usr=007}} {{tp|p=32464115|t=2020. Caution against corticosteroid-based COVID-19 treatment.|pdf=|usr=009}} {{tp|p=32519174|t=2020. What can we learn about corticosteroid therapy as a treatment for COVID-19?|pdf=|usr=009}} {{tp|p=32532461|t=2020. Eficacia de los pulsos de corticoides en pacientes con sindrome de liberacion de citocinas inducido por infeccion por SARS-CoV-2.|pdf=|usr=009}} {{tp|p=32514354|t=2020. High-dose, short-term corticosteroids for ARDS caused by COVID-19: a case series.|pdf=|usr=009}} {{tp|p=32491104|t=2020. Clinical characteristics and therapeutic procedure for a critical case of novel coronavirus pneumonia treated with glucocorticoids and non-invasive ventilator treatment.|pdf=|usr=009}} {{tp|p=32571831|t=2020. IMPACT OF GLUCOCORTICOID TREATMENT IN SARS-COV-2 INFECTION MORTALITY: A RETROSPECTIVE CONTROLLED COHORT STUDY.|pdf=|usr=010}} {{tp|p=32548723|t=2020. Impact of anti-rheumatic drugs and steroids on clinical course and prognosis of COVID-19.|pdf=|usr=010}} {{tp|p=32585180|t=2020. Use of inhaled corticosteroids in asthma and COVID-19 : Keep calm and carry on.|pdf=|usr=010}} {{tp|p=32588377|t=2020. Corticosteroids in diabetes patients infected with COVID-19.|pdf=|usr=010}} {{tp|p=32570995|t=2020. Short-Term Dexamethasone in Sars-CoV-2 Patients.|pdf=|usr=010}} {{tp|p=32576548|t=2020. Covid-19: Demand for dexamethasone surges as RECOVERY trial publishes preprint.|pdf=|usr=010}} {{tp|p=32546467|t=2020. Covid-19: Low dose steroid cuts death in ventilated patients by one third, trial finds.|pdf=|usr=010}} {{tp|p=32590699|t=2020. ACTH 1-24 and other melanocortins for COVID-19 treatment.|pdf=|usr=010}} {{tp|p=32566564|t=2020. Effectiveness and safety of glucocorticoids to treat COVID-19: a rapid review and meta-analysis.|pdf=|usr=011}} {{tp|p=32548616|t=2020. Corticosteroids in patients with COVID-19: what about the control group?|pdf=|usr=010}} {{tp|p=32451729|t=2020. Corticosteroid treatment in severe COVID-19 pneumonia: two cases and literature review.|pdf=|usr=011}} {{tp|p=32588877|t=2020. High-dose but not low-dose corticosteroids potentially delay viral shedding of patients with COVID-19.|pdf=|usr=011}} {{tp|p=32585016|t=2020. THE RIGHT TIME FOR STEROIDS IN COVID-19.|pdf=|usr=011}} {{tp|p=32603802|t=2020. Corticosteroid administration for viral pneumonia: COVID-19 and beyond.|pdf=|usr=011}} {{tp|p=32430057|t=2020. Adjuvant corticosteroid therapy for critically ill patients with COVID-19.|pdf=|usr=011}} {{tp|p=32610262|t=2020. Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician's perspective.|pdf=|usr=011}} {{tp|p=32394335|t=2020. Corticosteroids for critically ill COVID-19 patients with cytokine release syndrome: a limited case series.|pdf=|usr=011}} {{tp|p=32551464|t=2020. Dexamethasone for COVID-19? Not so fast.|pdf=|usr=011}} {{tp|p=32603493|t=2020. Methylprednisolone added to tocilizumab reduces mortality in SARS-CoV-2 pneumonia: An observational study.|pdf=|usr=011}} {{tp|p=32482571|t=2020. Consensus statement. Corticosteroid therapy in ENT in the context of the COVID-19 pandemic.|pdf=|usr=011}} {{ttp|p=32546811|t=2020. Coronavirus breakthrough: dexamethasone is first drug shown to save lives.|pdf=|usr=011}} {{tp|p=32538585|t=2020. Reply to: What we are talking about when we talk of steroid in COVID-19?|pdf=|usr=011}} {{tp|p=32530507|t=2020. Can steroids reverse the severe COVID-19 induced "cytokine storm"?|pdf=|usr=011}} {{tp|p=32383835|t=2020. Acute respiratory distress syndrome and steroids in the shadow of coronavirus disease 2019.|pdf=|usr=011}} {{tp|p=32426753|t=2020. Rationale for Prolonged Corticosteroid Treatment in the Acute Respiratory Distress Syndrome Caused by Coronavirus Disease 2019.|pdf=|usr=015}} {{tp|p=32536610|t=2020. Contrasting evidence for corticosteroid treatment for coronavirus-induced cytokine storm.|pdf=|usr=018}} {{tp|p=32616373|t=2020. The influence of corticosteroid on patients with COVID-19 infection: A meta-analysis.|pdf=|usr=017}} {{tp|p=32616381|t=2020. A critical evaluation of glucocorticoids in the management of severe COVID-19.|pdf=|usr=015}} {{tp|p=32634602|t=2020. Corticosteroid therapy for patients with CoVID-19 pneumonia: a before-after study.|pdf=|usr=012}} {{tp|p=32656044|t=2020. Pulse Therapy With Corticosteroids and Intravenous Immunoglobulin in the Management of Severe Tocilizumab-Resistant COVID-19: A Report of Three Clinical Cases.|pdf=|usr=014}} {{tp|p=32659271|t=2020. Pros and cons of corticosteroid therapy for COVID-19 patients.|pdf=|usr=014}} {{tp|p=32668178|t=2020. Inhaled Corticosteroids and COVID-19.|pdf=|usr=014}} {{tp|p=32671349|t=2020. Evidence of Steroids in Patients With Acute Respiratory Distress Syndrome in Coronavirus Disease 2019.|pdf=|usr=018}} {{tp|p=32675436|t=2020. Tailoring steroids in the treatment of COVID-19 pneumonia assisted by CT scans: Three case reports.|pdf=|usr=014}} {{tp|p=32696006|t=2020. Corticosteroid Administration Is Associated With Improved Outcome in Patients With Severe Acute Respiratory Syndrome Coronavirus 2-Related Acute Respiratory Distress Syndrome.|pdf=|usr=015}} {{tp|p=32697000|t=2020. Corticosteroids-induced osteonecrosis in COVID-19: a call for caution.|pdf=|usr=014}} {{tp|p=32719766|t=2020. Clinical Use of Short-Course and Low-Dose Corticosteroids in Patients With Non-severe COVID-19 During Pneumonia Progression.|pdf=|usr=017}} {{tp|p=32720612|t=2020. [Steroid pulse therapy (WAYFARER Study)].|pdf=|usr=014}} {{tp|p=32668164|t=2020. Reply to: Inhaled Corticosteroids and COVID-19.|pdf=|usr=014}} {{tp|p=32726951|t=2020. Efficacy of Corticosteroids in Patients with SARS, MERS and COVID-19: A Systematic Review and Meta-Analysis.|pdf=|usr=017}} {{tp|p=32730151|t=2020. Time-critical administration of corticosteroid rescue therapy for COVID-19 pneumonitis in a ward-based patient with chronic obstructive pulmonary disease.|pdf=|usr=018}} {{tp|p=32734777|t=2020. Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis.|pdf=|usr=017}} {{tp|p=32738928|t=2020. Inhaled corticosteroids in virus pandemics: a treatment for COVID-19?|pdf=|usr=017}} {{tp|p=32744591|t=2020. The Uncertain Role of Corticosteroids in the Treatment of COVID-19.|pdf=|usr=017}} {{tp|p=32744600|t=2020. The Uncertain Role of Corticosteroids in the Treatment of COVID-19-Reply.|pdf=|usr=017}} {{tp|p=32744622|t=2020. The Uncertain Role of Corticosteroids in the Treatment of COVID-19.|pdf=|usr=017}} {{tp|p=32756215|t=2020. Therapeutic response to corticosteroids in a critically ill patient with COVID-19: A case report.|pdf=|usr=017}} {{tp|p=32761166|t=2020. COVID-19 and Dexamethasone: A Potential Strategy to Avoid Steroid-Related Strongyloides Hyperinfection.|pdf=|usr=017}} {{tp|p=32760915|t=2020. Glucocorticoids save lives in COVID-19 patients.|pdf=|usr=017}} {{tp|p=32763262|t=2020. The proper use of corticosteroids for 2019-nCov pneumonia: Towards promising results?|pdf=|usr=017}} {{tp|p=32767349|t=2020. Corticosteroid therapy for patients with severe novel Coronavirus disease 2019.|pdf=|usr=017}} {{tp|p=32769659|t=2020. Corticosteroids in the Management of Pregnant Patients With Coronavirus Disease (COVID-19).|pdf=|usr=017}} {{tp|p=32778507|t=2020. COVID-19 and steroid therapy: Impact on diabetes.|pdf=|usr=017}} {{tp|p=32778829|t=2020. After 62 years of regulating immunity, dexamethasone meets COVID-19.|pdf=|usr=017}} {{tp|p=32792492|t=2020. Clinical characteristics and corticosteroids application of different clinical types in patients with corona virus disease 2019.|pdf=|usr=018}} {{tp|p=32795143|t=2020. Corticosteroid prevents COVID-19 progression within its therapeutic window: a multicentre, proof-of-concept, observational study.|pdf=|usr=018}} {{tp|p=32796809|t=2020. Short-Term Corticosteroid Therapy for Early Exacerbation of COVID-19 Pneumonia: A Case Report.|pdf=|usr=018}} {{tp|p=32802540|t=2020. Oral Corticosteroid Relieves Post-COVID-19 Anosmia in a 35-Year-Old Patient.|pdf=|usr=018}} {{ttp|p=32819962|t=2020. Steroids in COVID-19: An overview.|pdf=|usr=019}} {{tp|p=32829047|t=2020. CORTICOSTEROIDS IN THE TREATMENT OF SEVERE COVID-19 LUNG DISEASE.|pdf=|usr=018}} {{tp|p=32860209|t=2020. What we have to know about corticosteroids use during Sars-Cov-2 infection.|pdf=|usr=018}} {{tp|p=32860964|t=2020. Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19).|pdf=|usr=019}} {{tp|p=32861345|t=2020. Migratory Pulmonary Infiltrates in a Patient With COVID-19 Infection and the Role of Corticosteroids.|pdf=|usr=018}} {{tp|p=32868989|t=2020. Combination treatment of short-course systemic corticosteroid and favipiravir in a successfully treated case of critically ill COVID-19 pneumonia with COPD.|pdf=|usr=018}} {{tp|p=32876693|t=2020. Corticosteroids in COVID-19 ARDS: Evidence and Hope During the Pandemic.|pdf=|usr=019}} {{tp|p=32876689|t=2020. Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial.|pdf=|usr=019}} {{tp|p=32876695|t=2020. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial.|pdf=|usr=019}} {{tp|p=32876694|t=2020. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis.|pdf=|usr=019}} {{tp|p=32876697|t=2020. Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.|pdf=|usr=019}} {{tp|p=32878286|t=2020. Duration of COVID-19: Data from an Italian Cohort and Potential Role for Steroids.|pdf=|usr=018}} {{tp|p=32880102|t=2020. Efficacy Evaluation of Early, Low-Dose, Short-Term Corticosteroids in Adults Hospitalized with Non-Severe COVID-19 Pneumonia: A Retrospective Cohort Study.|pdf=|usr=018}} {{tp|p=32880390|t=2020. Systemic corticosteroids and mortality in severe and critical COVID-19 patients in Wuhan, China.|pdf=|usr=018}} {{tp|p=32881007|t=2020. Are the steroids a blanket solution for COVID-19? a systematic review and meta-analysis.|pdf=|usr=018}} {{tp|p=32888976|t=2020. Early short-course corticosteroids and furosemide combination to treat non-critically ill COVID-19 patients: An observational cohort study.|pdf=|usr=018}} {{tp|p=32900168|t=2020. Pasient med alvorlig covid-19 behandlet med steroider.|pdf=|usr=019}} {{tp|p=32903258|t=2020. Efficacy of corticosteroids in non-intensive care unit patients with COVID-19 pneumonia from the New York Metropolitan region.|pdf=|usr=019}} {{tp|p=32903363|t=2020. Corticosteroid Use in the Treatment of COVID-19: A Multicenter Retrospective Study in Hunan, China.|pdf=|usr=019}} {{tp|p=32931775|t=2020. The association between corticosteroid uses and mortality among severe COVID-19 patients.|pdf=|usr=019}} {{tp|p=32936438|t=2020. Steroids and COVID-19: We Need a Precision Approach, Not One Size Fits All.|pdf=|usr=019}} {{tp|p=32941927|t=2020. Corticosteroid therapy is associated with the delay of SARS-CoV-2 clearance in COVID-19 patients.|pdf=|usr=019}} {{tp|p=32948881|t=2020. Corticosteroid-related in-hospital hyperglycemia: does it negate mortality benefits in COVID-19?|pdf=|usr=019}} {{tp|p=32953385|t=2020. Steroids and COVID-19: We Need a Precision Approach, Not One Size Fits All.|pdf=|usr=019}} {{tp|p=32971254|t=2020. Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicentre study.|pdf=|usr=019}} {{tp|p=32976118|t=2020. Corticosteroids, COVID-19 pneumonia, and acute respiratory distress syndrome.|pdf=|usr=019}} {{tp|p=32983928|t=2020. The Application of Corticosteroids in COVID-19: A Two-edged Sword.|pdf=|usr=019}} {{tp|p=32986226|t=2020. Effect of Corticosteroid Therapy on the Duration of SARS-CoV-2 Clearance in Patients with Mild COVID-19: A Retrospective Cohort Study.|pdf=|usr=019}} {{tp|p=32988730|t=2020. Corticosteroids as adjunctive therapy in the treatment of coronavirus disease 2019: A report of two cases and literature review.|pdf=|usr=019}} {{tp|p=33005428|t=2020. Late i.v. steroid treatment for severe COVID-19-induced acute respiratory distress syndrome: a case report.|pdf=|usr=019}} {{tp|p=33007478|t=2020. Low-to-moderate dose corticosteroids treatment in hospitalized adults with COVID-19.|pdf=|usr=019}} {{tp|p=33008778|t=2020. Association of corticosteroids use and outcomes in COVID-19 patients: A systematic review and meta-analysis.|pdf=|usr=019}} {{ttp|p=33013412|t=2020. Efficacy and Safety of Corticosteroid Treatment in Patients With COVID-19: A Systematic Review and Meta-Analysis.|pdf=|usr=019}} {{ttp|p=33026460|t=2020. The ten reasons why corticosteroid therapy reduces mortality in severe COVID-19.|pdf=|usr=019}} {{tp|p=33043249|t=2020. Reactivation of SARS-CoV-2 after Asymptomatic Infection while on High-Dose Corticosteroids. Case Report.|pdf=|usr=020}} {{ttp|p=33055254|t=2020. The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting the viral replication-transcription complex in cultured cells.|pdf=|usr=020}} {{tp|p=33062586|t=2020. Corticosteroids: A Controversial Therapy for Coronavirus Disease 2019.|pdf=|usr=020}} {{ttp|p=33068560|t=2020. Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon.|pdf=|usr=020}} {{ttp|p=33083317|t=2020. Corticosteroids on the Management of Coronavirus Disease 2019 (COVID-19): A Systemic Review and Meta-Analysis.|pdf=|usr=020}} {{tp|p=33083917|t=2020. High versus standard doses of corticosteroids in severe COVID-19: a retrospective cohort study.|pdf=|usr=020}} {{tp|p=33094701|t=2020. Potential therapeutic use of corticosteroids as SARS CoV-2 main protease inhibitors: a computational study.|pdf=|usr=020}} {{tp|p=33100248|t=2020. Effectiveness of steroid treatment for SARS-CoV-2 pneumonia with COP-like reaction: a case report.|pdf=|usr=020}} {{tp|p=33103063|t=2020. Corticosteroids in COVID-19: Is it Rational? A Systematic Review and Meta-Analysis.|pdf=|usr=020}} {{tp|p=33107607|t=2020. Corticosteroids for COVID-19 patients requiring oxygen support? Yes, but not for everyone: Effect of corticosteroids on mortality and intensive care unit admission in patients with COVID-19 according to patients' oxygen requirements.|pdf=|usr=020}} {{tp|p=33115658|t=2020. Lack of detrimental effect of corticosteroids on antibody responses to SARS-CoV-2 and viral clearance in patients hospitalized with COVID-19.|pdf=|usr=020}} {{tp|p=33115684|t=2020. COVID-19, steroids and other immunomodulators: The jigsaw is not complete.|pdf=|usr=020}} {{tp|p=33119227|t=2020. Use of corticosteroids in SARS-CoV-2 infection: foe, or can they become a friend?|pdf=|usr=020}} {{tp|p=33121512|t=2020. Corticosteroids in severe COVID-19: a critical view of the evidence.|pdf=|usr=020}} {{tp|p=33123934|t=2020. Delayed hospital admission and high-dose corticosteroids potentially prolong SARS-CoV-2 RNA detection duration of patients with COVID-19.|pdf=|usr=020}} {{tp|p=33129791|t=2020. "Impact of Corticosteroids in COVID-19 Outcomes: Systematic Review and Meta-Analysis".|pdf=|usr=020}} {{tp|p=33141117|t=2020. Corticosteroid treatment in severe COVID-19 patients with acute respiratory distress syndrome.|pdf=|usr=020}} {{tp|p=33156381|t=2020. Impact of late administration of corticosteroids in COVID-19 ARDS.|pdf=|usr=020}} {{tp|p=33172477|t=2020. Corticosteroid therapy for coronavirus disease 2019-related acute respiratory distress syndrome: a cohort study with propensity score analysis.|pdf=|usr=020}} {{tp|p=33173161|t=2020. Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia.|pdf=|usr=020}} {{tp|p=33180190|t=2020. Steroid administration in the Covid-19 era; timing does matter!|pdf=|usr=020}} {{ttp|p=33183091|t=2020. Time-course analysis reveals that corticosteroids resuscitate diminished CD8+ T cells in COVID-19: a retrospective cohort study.|pdf=|usr=021}} {{tp|p=33183113|t=2020. Reduced risk of COVID-19 hospitalization in asthmatic and COPD patients: a benefit of inhaled corticosteroids?|pdf=|usr=021}} {{tp|p=33194871|t=2020. Late Worsening of COVID-19 Pneumonia: Successful Treatment with Ruxolitinib and Steroid.|pdf=|usr=020}} {{tp|p=33219091|t=2020. Early changes in immune cell subsets with corticosteroids in patients with solid tumors: implications for COVID-19 management.|pdf=|usr=021}} {{ttp|p=33221521|t=2020. Corticosteroid therapy in COVID-19 patients: Don't forget venous thromboembolism.|pdf=|usr=022}} {{tp|p=33229355|t=2020. Efficacite et innocuite des corticosteroides dans le traitement de la COVID-19 selon des donnees pour la COVID-19, d'autres infections aux coronavirus, l'influenza, la pneumonie extrahospitaliere et le syndrome de detresse respiratoire aigue : revue systematique et meta-analyse.|pdf=|usr=022}} {{tp|p=33235253|t=2020. Low-dose corticosteroid combined with immunoglobulin reverses deterioration in severe cases with COVID-19.|pdf=|usr=021}} {{tp|p=33235888|t=2020. Antivirals With Adjunctive Corticosteroids Prevent Clinical Progression of Early Coronavirus 2019 Pneumonia: A Retrospective Cohort Study.|pdf=|usr=021}} {{tp|p=33245242|t=2020. Corticosteroid use in viral pneumonia: experience so far and the dexamethasone breakthrough in coronavirus disease-2019.|pdf=|usr=022}} {{tp|p=33248469|t=2020. Corticosteroids for COVID-19: the search for an optimum duration of therapy.|pdf=|usr=021}} {{tp|p=33249430|t=2020. Effect of steroids on Covid-19 mortality risk: a Bayesian interpretation.|pdf=|usr=021}} {{tp|p=33249945|t=2020. Corticosteroids treatment in severe patients with COVID-19: a propensity score matching study.|pdf=|usr=021}} {{tp|p=33254551|t=2020. Can roflumilast become steroid-sparing alternative in the treatment of COVID-19?|pdf=|usr=022}} {{tp|p=33260010|t=2020. COVID-19 and non-COVID ARDS patients demonstrate a distinct response to low dose steroids- A retrospective observational study.|pdf=|usr=022}} {{ttp|p=33262415|t=2020. A systematic review of corticosteroid treatment for noncritically ill patients with COVID-19.|pdf=|usr=022}} {{tp|p=33263084|t=2020. Association between high-dose steroid therapy, respiratory function, and time to discharge in patients with COVID-19: Cohort study.|pdf=|usr=022}} {{tp|p=33264251|t=2020. Use of Corticosteroids in COVID-19: Should It Be Considered as a Standard-of-Care Therapy?|pdf=|usr=022}} {{tp|p=33274479|t=2020. Cyclosporine A plus low-dose steroid treatment in COVID-19 improves clinical outcomes in patients with moderate to severe disease. A pilot study.|pdf=|usr=022}} {{tp|p=33277573|t=2020. Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19.|pdf=|usr=022}} {{tp|p=33280066|t=2020. Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort Study.|pdf=|usr=022}} {{tp|p=33282314|t=2021. Improvement of COVID-19 with renal failure and paralytic ileus by using steroids.|pdf=|usr=022}} {{tp|p=33290446|t=2020. Efficacy of corticosteroid therapy in the treatment of long- lasting olfactory disorders in COVID-19 patients.|pdf=|usr=022}} {{tp|p=33298370|t=2020. Corticosteroids for Patients With Coronavirus Disease 2019 (COVID-19) With Different Disease Severity: A Meta-Analysis of Randomized Clinical Trials.|pdf=|usr=023}} {{tp|p=33301928|t=2020. Corticosteroids in patients hospitalised for COVID-19 pneumonia who require oxygen: observational comparative study using routine care data.|pdf=|usr=023}} {{tp|p=C7255263|t=2020. Use of corticosteroids in asthma and COPD patients with or without COVID-19.|pdf=|usr=015}} {{tp|p=C7298510|t=?. Steroids: A Therapeutic Option for COVID-19 Pneumonia Patients With ESRD?|pdf=|usr=015}} {{tp|p=C7303657|t=?. Systemic steroids and risk of fecal-oral shedding and increased transmission of SARS-Cov-2 in pemphigus cases???.|pdf=|usr=015}} {{tp|p=C7346767|t=2020. The use of corticosteroids for COVID-19 infection.|pdf=|usr=015}} {{tp|p=C7598544|t=2020. 153 Do Hydroxychloroquine Disease-Modifying Antirheumatic Agents or Steroids Serve to Prevent COVID-19 Infection?|pdf=|usr=023}} {{tp|p=C7661810|t=2020. Tocilizumab/unspecified corticosteroids: Spinal epidural abscess: 2 case report.|pdf=|usr=023}} {{tp|p=C7677437|t=2020. Enoxaparin sodium/methylprednisolone: Cytomegalovirus reactivation gastrointestinal haemorrhage and off-label use: case report.|pdf=|usr=023}} {{tp|p=C7726300|t=2020. Methylprednisolone/tocilizumab: Disseminated strongyloidiasis and off-label use: case report.|pdf=|usr=023}} {{tp|p=C7726305|t=2020. Gasorelin/prednisolone: COVID-19 infection and weight increase : case report.|pdf=|usr=023}} {{tp|p=32696008|t=2020. The Combination of Tocilizumab and Methylprednisolone Along With Initial Lung Recruitment Strategy in Coronavirus Disease 2019 Patients Requiring Mechanical Ventilation: A Series of 21 Consecutive Cases.|pdf=|usr=015}} {{tp|p=32772069|t=2020. Clinical Outcomes Associated with Methylprednisolone in Mechanically Ventilated Patients with COVID-19.|pdf=|usr=017}} {{tp|p=32785710|t=2020. Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With COVID-19 (Metcovid): A Randomised, Double-Blind, Phase IIb, Placebo-Controlled Trial.|pdf=|usr=019}} {{tp|p=32816700|t=2020. Response to: 'High dosage of Methylprednisolone as a rescue, second-line treatment in COVID-19 patients who failed to respond to Tocilizumab' by Conticini et al.|pdf=|usr=018}} {{tp|p=32816701|t=2020. High dosage of methylprednisolone as a rescue, second-line treatment in COVID-19 patients who failed to respond to tocilizumab.|pdf=|usr=018}} {{tp|p=32845289|t=2020. Methylprednisolone for COVID-19: Was Benjamin Rush prescient?|pdf=|usr=018}} {{tp|p=32893160|t=2020. Outcome of early-stage combination treatment with favipiravir and methylprednisolone for severe COVID-19 pneumonia: A report of 11 cases.|pdf=|usr=019}} {{tp|p=32943404|t=2020. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial.|pdf=|usr=019}} {{tp|p=32954492|t=2020. The role of methylprednisolone on preventing disease progression for hospitalized patients with severe COVID-19.|pdf=|usr=019}} {{tp|p=32960899|t=2020. Second week methyl-prednisolone pulses improve prognosis in patients with severe coronavirus disease 2019 pneumonia: An observational comparative study using routine care data.|pdf=|usr=019}} {{tp|p=32995261|t=2020. Methylprednisolone pulse therapy: An alternative management of severe COVID-19.|pdf=|usr=019}} {{tp|p=33072814|t=2020. Prolonged Low-Dose Methylprednisolone in Patients With Severe COVID-19 Pneumonia.|pdf=|usr=020}} {{tp|p=33109497|t=2020. Computational studies reveal mechanism by which quinone derivatives can inhibit SARS-CoV-2. Study of embelin and two therapeutic compounds of interest, methyl prednisolone and dexamethasone.|pdf=|usr=020}} {{tp|p=33176176|t=2020. Early, low-dose, short-term methylprednisolone decreased the mortality in critical COVID-19 patients: A multicenter retrospective cohort study.|pdf=|usr=020}} {{tp|p=33194485|t=2020. Comparison of Efficacy of Dexamethasone and Methylprednisolone in Improving PaO2/FiO2 Ratio Among COVID-19 Patients.|pdf=|usr=021}} {{tp|p=33200031|t=2020. Comparison of efficacy of dexamethasone and methylprednisolone in moderate to severe covid 19 disease.|pdf=|usr=021}} {{tp|p=33219551|t=2020. High-dose methylprednisolone in nonintubated patients with severe COVID-19 pneumonia.|pdf=|usr=021}} {{tp|p=33220354|t=2020. Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: an observational cohort study.|pdf=|usr=022}} {{tp|p=33225306|t=2020. Intravenous Immunoglobulin Plus Methylprednisolone Mitigate Respiratory Morbidity in Coronavirus Disease 2019.|pdf=|usr=021}} {{tp|p=33225870|t=2020. In silico screening predicts common cold drug Dextromethorphan along with Prednisolone and Dexamethasone can be effective against novel Coronavirus disease (COVID-19).|pdf=|usr=021}} {{tp|p=33230502|t=2020. Successful recovery from coronavirus disease 2019 in a living kidney transplant recipient using low-dose methylprednisolone.|pdf=|usr=022}} {{tp|p=33318924|t=2020. Successful treatment with methyl-prednisolone pulses for the late phase of COVID-19 with respiratory failure: A single-center case series.|pdf=|usr=023}} {{tp|p=C7212250|t=2020. Prednisone: Coronavirus disease 2019: case report.|pdf=|usr=015}} {{tp|p=C7303433|t=2020. Methylprednisolone: Decrease in T cell count following off label use: case report.|pdf=|usr=015}} {{tp|p=C7317072|t=2020. Methylprednisolone/prednisone: Accelerated viral replication following an off-label treatment: case report.|pdf=|usr=015}} {{tp|p=C7648232|t=2020. Prednisolone/tacrolimus: COVID-19 infection: case report.|pdf=|usr=023}} {{tp|p=33229384|t=2020. Dexamethasone or hydrocortisone in COVID-19?|pdf=|usr=021}} {{tp|p=33232277|t=2020. Estimating the release of inflammatory factors and use of glucocorticoid therapy for COVID-19 patients with comorbidities.|pdf=|usr=021}} {{tp|p=33308854|t=?. Cuestiones por resolver en el tratamiento con glucocorticoides de la infección COVID-19.|pdf=|usr=023}} {{tp|p=C7351423|t=?. Effectiveness of corticoid pulses in patients with cytokine storm syndrome induced by SARS-CoV-2 infection?.|pdf=|usr=015}} {{tp|p=C7648207|t=2020. Adalimumab/anakinra/dexamethasone: COVID-19 infection cytomegalovirus reactivation and off-label use: case report.|pdf=|usr=023}} {{tp|p=32620554|t=2020. Dexamethasone in the management of covid -19.|pdf=|usr=012}} {{tp|p=32636478|t=2020. Dexamethasone to the rescue.|pdf=|usr=015}} {{tp|p=32674177|t=2020. Therapie mit Dexamethason bei Patienten mit COVID-19.|pdf=|usr=014}} {{tp|p=32678530|t=2020. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report.|pdf=|usr=014}} {{tp|p=32684095|t=2020. Worrying situation regarding the use of dexamethasone for COVID-19.|pdf=|usr=018}} {{tp|p=32690491|t=2020. Dexamethasone for COVID-19: preliminary findings.|pdf=|usr=014}} {{tp|p=32706553|t=2020. Audio Interview: Dexamethasone and Covid-19.|pdf=|usr=014}} {{tp|p=32740972|t=2020. Dexamethasone therapy in COVID-19 patients: implications and guidance for the management of blood glucose in people with and without diabetes.|pdf=|usr=017}} {{tp|p=32747742|t=2020. Dexamethasone nanomedicines for COVID-19.|pdf=|usr=017}} {{tp|p=32791213|t=2020. Dexamethasone: A boon for critically ill COVID-19 patients?|pdf=|usr=018}} {{tp|p=32874905|t=2020. Dexamethasone in severe COVID-19 infection: A case series.|pdf=|usr=018}} {{tp|p=32887677|t=2020. Covid-19: Hydrocortisone can be used as alternative to dexamethasone, review finds.|pdf=|usr=018}} {{tp|p=32896649|t=2020. Dexamethasone to combat cytokine storm in COVID-19: Clinical trials and preliminary evidence.|pdf=|usr=019}} {{tp|p=32922210|t=2020. Hydroxychloroquine and dexamethasone in COVID-19: who won and who lost?|pdf=|usr=019}} {{tp|p=32922517|t=2020. Dexamethasone in the era of COVID-19: friend or foe? An essay on the effects of dexamethasone and the potential risks of its inadvertent use in patients with diabetes.|pdf=|usr=019}} {{ttp|p=32924825|t=2020. Computational insight of dexamethasone against potential targets of SARS-CoV-2.|pdf=|usr=019}} {{tp|p=33000510|t=2020. Molecular and functional resemblance of dexamethasone and quercetin: A paradigm worth exploring in dexamethasone-nonresponsive COVID-19 patients.|pdf=|usr=020}} {{tp|p=33023445|t=2020. Epidemiological Situation and Efficacy of Dexamethasone for the treatment planning of COVID-19: A perspective review.|pdf=|usr=020}} {{tp|p=33035967|t=2020. COVID-19, myocardial edema and dexamethasone.|pdf=|usr=020}} {{tp|p=33053024|t=2020. Sindrome do desconforto respiratorio agudo associada a COVID-19 tratada com Dexametasona (CoDEX).|pdf=|usr=020}} {{tp|p=33063792|t=2020. Molecular determinants of vascular transport of dexamethasone in COVID-19 therapy.|pdf=|usr=020}} {{tp|p=33077267|t=2020. Chez les sujets hospitalises pour COVID-19, est-ce que la dexamethasone diminue la mortalite a 28jours comparativement au traitement standard ?|pdf=|usr=020}} {{tp|p=33129421|t=2020. Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties.|pdf=|usr=020}} {{tp|p=33137605|t=2020. Can dexamethasone prevent the seizures induced by SARS-CoV-2 infection?|pdf=|usr=020}} {{tp|p=33163859|t=2020. Dexamethasone for the Treatment of Coronavirus Disease (COVID-19): a Review.|pdf=|usr=020}} {{tp|p=33233748|t=2020. Biomimetic Nanoparticles Potentiate the Anti-Inflammatory Properties of Dexamethasone and Reduce the Cytokine Storm Syndrome: An Additional Weapon against COVID-19?|pdf=|usr=021}} {{tp|p=33251412|t=2020. Chemocentric Informatics Analysis: Dexamethasone Versus Combination Therapy for COVID-19.|pdf=|usr=021}} {{tp|p=33293892|t=2020. Dexamethason.|pdf=|usr=023}} {{tp|p=C7343652|t=2020. The use of dexamethasone in the treatment of COVID-19.|pdf=|usr=015}}

Zurück zur Seite Corticosteroids.